Table 2 Baseline characteristics of the study group based on 8312 non-TNBC patients and 844 TNBC patients included in the study
Non-TNBC | TNBC | ||||
|---|---|---|---|---|---|
8312 (90.8%) | 844 (9.2%) | ||||
Mean | N | Mean | N | p-value | |
Age (range) | 61.2 (22; 97) | 8312 | 57.7 (27; 97) | 844 | <0.001 |
Postmenopausal | 74.8% | 6220 | 66% | 557 | <0.001 |
T 1 | 55.3% | 4600 | 48.5% | 409 | <0.001 |
T 2 | 36% | 2995 | 41.4% | 349 | |
T 3 | 3.8% | 313 | 5.9% | 50 | |
T4 | 4.9% | 404 | 4.3% | 36 | |
Node negative | 59.9% | 4979 | 62.6% | 528 | 0.133 |
1-3 | 23.8% | 1978 | 20% | 169 | |
>3 | 16.3% | 1355 | 17.4% | 147 | |
G 1 | 9.9% | 820 | 1.4% | 12 | <0.001 |
G 2 | 65.5% | 5447 | 25.4% | 214 | |
G 3 | 24.6% | 2045 | 73.2% | 618 | |
ASA Score >3 | 21.7% | 1068 | 18.3% | 94 | 0.072 |
NYHA Class > III | 3.5% | 92 | 4.0% | 12 | 0.652 |
Myocardial infarction, stroke, or TIA | 4.2% | 230 | 3.4% | 19 | 0.340 |
HR negative | 5.8% | 481 | 100.0% | 844 | <0.001 |
HR IRS 1-5 | 23.5% | 1953 | 0.0% | 0 | |
HR positive | 70.7% | 5878 | 0.0% | 0 | |
Her2neu positive | 17.7% | 1468 | 0.0% | 0 | <0.001 |
Endocrine therapy | 82.0% | 6816 | 5.6% | 47 | <0.001 |
Chemotherapy | 43.0% | 3575 | 77.1% | 651 | <0.001 |
Mastectomy | 29.0% | 2414 | 26.7% | 225 | 0.145 |
Radiotherapy | 79.2% | 6579 | 80.3% | 678 | 0.420 |